Completed PHASE2 INTERVENTIONAL 1-arm NCT00176800

Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma

Pre-Operative Chemoradiation Followed by Post-Operative Tetrathiomolybdate (TM) in Patients With Loco-Regional Esophageal Carcinoma (UMCC 2001-007)

Sponsor: University of Michigan Rogel Cancer Center

Conditions Esophageal Carcinoma

Interventions Radiation Surgery Tetrathiomolybdate (TM)

Updated 9 times since 2017 Last updated: Jul 12, 2016 Started: Nov 30, 2001 Primary completion: Feb 28, 2006 Completion: May 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Esophageal Carcinoma, this trial is completed. The trial is conducted by University of Michigan Rogel Cancer Center and has accumulated 9 data snapshots since 2001. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Feb 2019 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Feb 2019 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Nov 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Michigan Rogel Cancer Center

Data source: University of Michigan Rogel Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ann Arbor, United States